Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Phase 3

Active, not recruiting

Conditions: Alagille Syndrome (ALGS)

Interventions: Drug: TAK-625

First Posted Date: 2022-09-16

Last Posted Date: 2024-10-11

Lead Sponsor: Takeda

Target Recruit Count: 7

Registration Number: NCT05543174

Locations: 🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
🇯🇵
Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Osaka University Hospital, Suita, Osaka, Japan

and more 5 locations

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Velaglucerase Alfa

First Posted Date: 2022-09-07

Last Posted Date: 2024-11-22

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT05529992

Locations: 🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China

and more 7 locations

A Study of TAK-341 in Treatment of Multiple System Atrophy

Phase 2

Active, not recruiting

Conditions: Multiple System Atrophy

Interventions: Drug: TAK-341
Drug: Placebo

First Posted Date: 2022-09-02

Last Posted Date: 2024-08-01

Lead Sponsor: Takeda

Target Recruit Count: 159

Registration Number: NCT05526391

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 38 locations

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Phase 3

Active, not recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Drug: TAK-771

First Posted Date: 2022-08-24

Last Posted Date: 2024-02-20

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05513586

Locations: 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan

and more 6 locations

A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema

Recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Drug: Icatibant

First Posted Date: 2022-08-22

Last Posted Date: 2024-10-02

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT05509569

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study of People With CD30 Positive Lymphoma in China

Completed

Conditions: Lymphoma

First Posted Date: 2022-08-18

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 1006

Registration Number: NCT05506774

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

and more 8 locations

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Phase 4

Recruiting

Conditions: Mucopolysaccharidosis (MPS)
Hunter Syndrome

Interventions: Drug: ELAPRASE
Drug: Rituximab
Drug: Methotrexate
Drug: Intravenous Immunoglobulin (IVIG)

First Posted Date: 2022-08-10

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT05494593

Locations: 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 8 locations

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Completed

Conditions: Hereditary Angioedema (HAE)

Interventions: Other: No Intervention

First Posted Date: 2022-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Takeda

Target Recruit Count: 85

Registration Number: NCT05489640

Locations: 🇬🇧
Sciensus, London, United Kingdom

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2022-08-01

Last Posted Date: 2023-12-01

Lead Sponsor: Takeda

Target Recruit Count: 8

Registration Number: NCT05481437

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Phase 2

Withdrawn

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Biological: Purified Inactivated Zika Virus Vaccine (PIZV)

First Posted Date: 2022-07-22

Last Posted Date: 2024-03-13

Lead Sponsor: Takeda

Registration Number: NCT05469802

Locations: 🇺🇸
CenExel Research Centers of America, Oakland Park, Florida, United States
🇺🇸
AMR East Wichita, Formerly Heartland Associates East Wichita, an AMR company, Wichita, Kansas, United States
🇺🇸
AMR Lexington, Formerly Central Kentucky Research Associates, an AMR company, Lexington, Kentucky, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy